Abstract: A hearing health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C (Calcium Ascorbate), Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q10, R-alpha Lipoic Acid, L-Carnitine and mixtures thereof.
Type:
Grant
Filed:
April 1, 2008
Date of Patent:
December 22, 2009
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, Gerald M. Haase, William C. Cole
Abstract: A heart and pulmonry health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the formulation comprising dietary micronutrients and endogenous antioxidants, the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C, Vitamin D3 (Cholecalciferol), B Vitamins, Biotin, Pantothenic Acid (as D-Calcium Pantothenate), Calcium Citrate, Magnesium Citrate, Zinc Glycinate, Selenium (Seleno-L-Methionine), Chromium (as Chromium Picolinate), Mixed Carotenoids and mixtures thereof, and the endogenous antioxidants are selected from a group consisting essentially of N-Acetyl Cysteine (NAC), Coenzyme Q10, R-alpha Lipoic Acid, Omega-3 fatty Acid, and L-Carnitine and mixtures thereof.
Type:
Grant
Filed:
June 6, 2008
Date of Patent:
December 8, 2009
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, Gerald M. Haase, William C. Cole
Abstract: 2-Nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, useful in the treatment of tuberculosis are disclosed. Methods of treating tuberculosis using the 2-nitroimidazolyl-alkylaminoquinolines, and compositions containing the same, also are disclosed.
Type:
Grant
Filed:
August 23, 2007
Date of Patent:
November 17, 2009
Assignee:
Evanston Northwestern Healthcare
Inventors:
Maria V. Papadopoulou, William D. Bloomer
Abstract: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.
Type:
Grant
Filed:
May 19, 2005
Date of Patent:
November 17, 2009
Assignee:
Cognition Pharmaceuticals LLC
Inventors:
Mel H. Epstein, Kjesten A. Wiig, Randall L. Carpenter
Abstract: The invention concerns the combination of a short-acting hypnotic agent and a compound of formula (I): Wherein X, Y, Z, A, B, D, Ar, R1 and R2 are as defined herein. The combination of this invention is useful in treating a variety of sleep disorders.
Type:
Grant
Filed:
February 6, 2008
Date of Patent:
November 17, 2009
Assignee:
Aventis Pharmaceuticals Inc
Inventors:
Gary Emmons, Sathapana Kongsamut, Craig N. Karson, Corrine M. Legoff
Abstract: The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.
Type:
Grant
Filed:
November 18, 2005
Date of Patent:
November 3, 2009
Assignee:
Cincinnati Children's Hospital Medical Center
Inventors:
Yi Zheng, Huzoor Akbar, David A. Williams, Wieslaw Adam Mazur
Abstract: Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
Type:
Grant
Filed:
December 11, 2006
Date of Patent:
October 27, 2009
Assignee:
AstraZeneca AB
Inventors:
Thomas R. Simpson, James Kang, Jeffrey S. Albert, Cristobal Alhambra, Gerald M. Koether, James Woods, Yan Li
Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
July 15, 2004
Date of Patent:
October 27, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
Abstract: The invention relates to paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of general formula (1): wherein X?C?O, C—S—CH3, C—S, —C—NHOH, Z—C or N, Y— with the adjacent ring, a phenyl or thienyl group, the ring(s) of said derivatives being optionally substituted with one or more halogen atoms, hydroxy, alkylenehydroxy, alkynealkylenehydroxy, alkynehydroxycyclohexyl, alkyl, alkoxy, alkylenealkoxy, or alkylenecyano groups where the alkylene group is either saturated or unsaturated, the groups having a straight or branched chain with C1 to C18, said chain being optionally substituted with one or more hydroxy or amino groups, or one or more trifluoromethyl, —COM, —COOM, or —CH2COOM groups (where M=H, C1 to C18 straight or branched chain alkyl, optionally substituted with one or more hydroxy and/or amino groups) nitroso, or cyano, R5?H, or C1 to C5 alkyl and R12?H, or —C—CO2—(CH3)3 and the phy
Type:
Grant
Filed:
April 12, 2007
Date of Patent:
October 20, 2009
Assignees:
Centre National de la Recherche Scientifique - CNRS, Universitè{grave over ( )} de Poitiers
Abstract: Formulations for minimizing damage to at least one of cells, organs and systems within the body of a subject afflicted with Diabetes Mellitus. The invention additionally encompasses methods for minimizing said damage which comprise administering to subjects in need thereof a therapeutic amount of a formulation(s) according to the invention.
Type:
Grant
Filed:
November 20, 2007
Date of Patent:
October 20, 2009
Assignee:
Premier Micronutrient Corporation
Inventors:
Kedar N. Prasad, William C. Cole, Gerald M. Haase
Abstract: An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of ?2C-adrenoceptor and is useful in preventing and treating disorders attributable to ?2C-adrenoceptor. The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.
Abstract: A method is provided for first line treatment of type 2 diabetes employing a combination of metformin and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or hemoglobin 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes.
Abstract: Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
Type:
Grant
Filed:
November 28, 2005
Date of Patent:
September 22, 2009
Assignee:
Merck Sharp & Dohme Limited
Inventors:
Mark Stuart Chambers, Neil Roy Curtis, Emanuela Gancia, Myra Gilligan, Alexander Charles Humphries, Tamara Ladduwahetty, Robert James Maxey, Kevin John Merchant
Abstract: It is an object of the present invention to provide an external preparation having enhanced transdermal penetration of a mast cell degranulation inhibitor. It is also an object of the present invention to provide a method for improving the photostability of a preparation containing a mast cell degranulation inhibitor. The present invention provides an external preparation containing a mast cell degranulation inhibitor and a topical anesthetic. Further, the method for enhancing the photostability of a preparation containing a mast cell degranulation inhibitor according to the present invention includes adding a topical anesthetic thereto.
Abstract: This invention generally relates to derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.
Type:
Grant
Filed:
April 10, 2003
Date of Patent:
September 22, 2009
Assignee:
Ranbaxy Laboratories Limited
Inventors:
Anita Mehta, Arundutt Viswanatham Silamkoti, Jang Bahadur Gupta
Abstract: Disclosed are compounds of formula (I): wherein R1 and R4 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases, cardiovascular disease and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
Type:
Grant
Filed:
May 31, 2007
Date of Patent:
September 22, 2009
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
John David Ginn, Ronald John Sorcek, Michael Robert Turner, Erick Richard Roush Young
Abstract: The present invention relates to 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula IA and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Abstract: The use of angelicin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia is described. A structural analogue which is particularly preferred for this purpose is bergapten.
Type:
Grant
Filed:
July 30, 2003
Date of Patent:
August 11, 2009
Assignees:
Universita' Degli Studi Di Ferrara, Associazione Veneta Per La Lotta Alla Talassemia
Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
Type:
Grant
Filed:
May 16, 2007
Date of Patent:
August 11, 2009
Assignee:
Bristol-Myers Squibb Company
Inventors:
Tao Wang, Ying Han, John F. Kadow, Zhongxing Zhang, Nicholas A. Meanwell
Abstract: The present invention provides an MMP-inhibitory composition comprising chalcone or its derivatives. They inhibit the MMPs in collagenase subfamily as well as those in gelatinase subfamily. The MMP inhibitory activity of chalcone derivatives was similar to or greater than that of parent compound, chalcone. Chalcone or its derivatives of the present invention inhibit activity of matrix metalloproteinase, so that it can be applied to treat and prevent diseases related to matrix metalloproteinase.
Type:
Grant
Filed:
May 3, 2004
Date of Patent:
August 11, 2009
Assignee:
Angiolab, Inc.
Inventors:
Min-Young Kim, Byung-Young Park, Kyoung-Mi Kim, Nack-Do Sung, Pyung-Keun Myung